SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
SeaStar Medical held its annual meeting of shareholders on June 17, 2026, with stockholders voting on four proposals: election of Class I director John Neuman, approval of an amended 2022 Omnibus Incentive Plan increasing authorized shares from 207,046 to 896,546, ratification of WithumSmith+Brown, PC as independent auditor, and adjournment authority. All four proposals passed.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from Neonode's 2026 Annual Meeting of Stockholders held on June 17, 2026, covering three proposals: election of directors (Peter Lindell and Per Löfgren), ratification of Crowe LLP as independent auditor, and an advisory say-on-pay vote. The filing presents voting tallies for each proposal, which is the quintessential content of Item 5.07 shareholder_vote_results disclosures.
View raw filing on EDGAR →AXT's subsidiary Tongmei entered into a long-term supply agreement with Casela committing Casela to purchase approximately $25.4 million of InP wafer substrates during 2027, with 50% prepayment required within 15 business days. While this is a material commercial contract (Item 1.01), it is fundamentally a supply/customer agreement rather than a merger, acquisition, disposition, or change of control. The agreement secures significant committed revenue and prepayment but does not fit the specific M&A taxonomy categories, warranting classification as other_material.
View raw filing on EDGAR →The Company amended pre-funded warrants originally issued in October 2025 to remove exercisability restrictions, enabling R01 Fund LP and Framework Ventures IV L.P. to exercise their warrants on a cashless basis, resulting in the issuance of an aggregate of 22,614,600 shares of Common Stock and increasing outstanding shares from approximately 27.8 million to 50.4 million shares.
View raw filing on EDGAR →This Item 5.07 filing discloses the complete results of GeoVax Labs' annual stockholder meeting held on June 17, 2026, including voting outcomes on director elections, warrant exercise proposals, auditor ratification, and executive compensation advisory votes. The disclosure of shareholder voting results on material matters such as director elections and dilutive warrant issuances (totaling over 3.8 million shares) is material to investors assessing corporate governance and capital structure changes.
View raw filing on EDGAR →The disclosure centers on the Compensation Committee's approval of equity awards (1,961,986 PSUs and 783,618 RSUs) granted to executive officers including the CEO, CFO, and Chief Accounting Officer under the 2026 Equity Incentive Plan. This is a classic compensatory arrangement disclosure under Item 5.02(e), with specific vesting schedules and performance targets tied to stock price appreciation over three years. The awards represent 37% of authorized shares and are material to investor assessment of executive compensation.
View raw filing on EDGAR →The Company extended the expiration date of a rights offering from June 23 to June 29, 2026, at a subscription price of $6.90 per share. While this is a material capital-raising event affecting shareholder dilution and the Company's financing timeline, it does not fit neatly into the more specific categories (dilutive_issuance typically covers the initial announcement of an unregistered equity sale, not an extension of an existing offering). The extension itself is material to investors tracking the offering's progress and their subscription decision window.
View raw filing on EDGAR →The filing discloses a "strategic investment in Skyline Instruments Corporation" announced via press release on June 17, 2026. While the prose does not specify the investment amount, structure, or whether it constitutes a material acquisition under Item 1.01, a strategic investment by a public company is typically material to investors assessing the registrant's capital allocation and business strategy. The disclosure does not fit the more specific categories (ma_activity would require clearer language about acquisition/merger/change of control; dilutive_issuance would require equity issuance detail). Classified as other_material pending fuller details in the attached exhibit.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of Fluent, Inc.'s 2026 Annual Meeting of Stockholders held on June 17, 2026. The filing presents voting results for eight matters, including election of seven directors, say-on-pay advisory vote, auditor ratification, and approval of equity-related proposals. Shareholder vote results are material to investors as they confirm governance outcomes and approval of significant corporate actions such as equity plan amendments and warrant issuances.
View raw filing on EDGAR →The Compensation Committee approved and adopted the Senior Executive Annual Bonus Plan on June 15, 2026, establishing a compensatory arrangement for executive officers and designated employees. The plan specifies performance metrics, payment mechanisms (cash or stock under the 2022 Equity Incentive Plan), and clawback provisions. This is a material disclosure of a new compensation plan affecting executive officers, fitting squarely within the exec_compensation category.
View raw filing on EDGAR →Twilio held its Annual Meeting of stockholders on June 16, 2026, with voting results disclosed on June 17, 2026. Five proposals were voted on and approved by substantial majorities: election of four Class I directors, ratification of KPMG LLP as independent auditor, advisory vote on named executive officer compensation, and approval of amendments and restatements to the 2016 Stock Option and Incentive Plan and 2016 Employee Stock Purchase Plan.
View raw filing on EDGAR →The disclosure announces a Board declaration of an annual cash dividend of $0.55 per share with specific payment and record dates. While dividend declarations are routine corporate actions, this is material to shareholders as it affects their investment returns and the company's capital allocation. However, it does not fit neatly into the more specific event categories (not earnings, not executive-related, not M&A, not a restatement or going-concern issue), so "other_material" is the most appropriate classification.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from the June 12, 2026 Annual Meeting of Stockholders, covering three proposals: election of three Class I directors (Michael Singer, Timothy Springer, and Patrick Zenner), advisory approval of named executive officer compensation, and ratification of Ernst & Young LLP as independent auditor. The filing explicitly states the vote tallies and outcomes for each proposal, which is the core content of Item 5.07.
View raw filing on EDGAR →Mr. Steven Berman, the former Chief Executive Officer, resigned effective June 3, 2026, as part of a mutual settlement agreement resolving disputes arising from his suspension in May 2024 and an internal investigation into allegations against him. The departure of a CEO following a governance crisis and investigation is material to investors' assessment of the company's leadership and stability.
View raw filing on EDGAR →This is a clear restatement disclosure under Item 4.02. Management concluded on June 11, 2026 that previously issued condensed consolidated financial statements in two quarterly 10-Q filings should no longer be relied upon due to an error in the calculation of weighted-average shares outstanding used in EPS calculations. The error resulted in material overstatements and understatements of basic and diluted EPS across multiple periods (ranging from $0.08 to $4.26 per share), and the Company intends to file amended 10-Qs to restate the affected financial statements. This is a quintessential restatement event.
View raw filing on EDGAR →Groupon held its 2026 Annual Meeting of Stockholders on June 11, 2026, with shareholders voting on four proposals: election of six directors, ratification of Deloitte & Touche LLP as independent auditor, advisory approval of named executive officer compensation, and approval of a certificate amendment for officer exculpation provisions.
View raw filing on EDGAR →This Item 5.07 disclosure reports the final voting results from Sabra Health Care REIT's annual meeting of stockholders held on June 17, 2026. The filing presents detailed voting tallies for three matters: election of seven directors, ratification of PricewaterhouseCoopers LLP as independent auditor, and advisory approval of named executive officer compensation. Shareholder vote results are material to investors as they confirm governance composition and audit oversight for the fiscal year.
View raw filing on EDGAR →The exhibit announces a 1-for-2 reverse stock split (share consolidation) effective June 25, 2026, approved by shareholders at the May 28, 2026 AGM. While a reverse split is technically a capital restructuring rather than a distribution, it materially affects share structure and is disclosed as a significant corporate action. The company cites Nasdaq listing-standard compliance and share-price support as rationales, indicating potential delisting risk if the split fails. This is material to investors assessing the registrant's compliance status and market position.
View raw filing on EDGAR →MIRA Pharmaceuticals disclosed submission of a Phase 2a clinical trial protocol to the FDA for Ketamir-2, a proprietary oral NMDA receptor modulator for chemotherapy-induced peripheral neuropathy, with FDA acknowledgment of receipt. This represents a material clinical development milestone for a pharmaceutical company, but does not fit neatly into the standard taxonomy categories (not an earnings release, executive change, M&A activity, impairment, or other defined event types). The advancement of a lead drug candidate through FDA regulatory stages is material to investors assessing the company's pipeline and prospects.
View raw filing on EDGAR →J-Star received a Staff Delisting Determination Letter from Nasdaq on June 12, 2026, for failure to maintain the minimum bid price of $1.00 per share under Nasdaq Listing Rule 5550(a)(2). The company is requesting a hearing before the Nasdaq Hearings Panel to appeal the determination and request additional time to regain compliance. This is a classic delisting-risk disclosure under Item 3.01 equivalent, materially affecting investor assessment of the registrant's continued listing status.
View raw filing on EDGAR →The filing discloses the completion of a material acquisition of Cataneo GmbH for $19.5 million in aggregate consideration ($9 million cash plus 250,792 shares of common stock valued at $37.88 per share). Item 7.01 confirms all pre-closing obligations and conditions have been satisfied, and the Closing has occurred. This is a significant M&A transaction requiring disclosure under Item 1.01 (incorporated by reference to the April 30, 2026 8-K) and Item 3.02 (unregistered equity issuance as part of consideration).
View raw filing on EDGAR →The filing discloses Item 5.07 results from the Company's June 12, 2026 Annual Stockholders' Meeting, including voting outcomes on seven proposals: election of seven directors, ratification of auditor (Wipfli LLP), approval of the 2026 Equity Incentive Plan, approval of convertible note issuance authority, amendment to increase authorized shares from 100M to 750M, advisory vote on executive compensation, and advisory vote frequency. These results are material to investors as they reflect shareholder approval of significant corporate actions including equity plan adoption and substantial share authorization increases.
View raw filing on EDGAR →Genius Group announced the cancellation of 26.6 million Class A Ordinary Shares (22% of public float) this week, comprising a 20-million-share return from ERL and a 6.6-million-share repurchase. While technically a share cancellation rather than a traditional dividend, this represents a return of capital to shareholders through reduction of issued share capital and is explicitly framed as part of the Company's capital allocation strategy to increase Net Asset Value per Share (NAVPS). The magnitude (22% of public float) and strategic intent make this material to investors assessing shareholder value.
View raw filing on EDGAR →SharonAI Holdings entered into Securities Purchase Agreements on June 17, 2026 for a private offering of approximately 6.7 million shares of Class A ordinary common stock at $68.73 per share, pre-funded warrants, and $600 million of 4.75% Convertible Senior Notes due 2032, generating approximately $1.5 billion in aggregate gross proceeds. The convertible notes are convertible into up to approximately 13.1 million shares of Common Stock at an initial conversion price of $95.66 per share. This is a material dilutive equity issuance raising substantial capital for the company's NVIDIA compute collaboration and AI Factory expansion.
View raw filing on EDGAR →Liberty Star entered into a Securities Purchase Agreement with 1800 Diagonal Lending LLC to issue a $73,700 convertible promissory note with 10% Original Issue Discount, convertible into common stock. This is a dilutive issuance of equity securities (via conversion rights embedded in the convertible note), a material financing event for a small-cap uranium exploration company that signals capital-raising pressure and future shareholder dilution.
View raw filing on EDGAR →XCF Global terminated a $50 million equity purchase agreement with Helena Global Investment Opportunities I LTD. that had reserved approximately 55 million shares for potential issuance. While the termination itself eliminates dilution risk, the core event disclosed is the unwinding of a dilutive equity arrangement that previously posed material overhang and dilution concerns. The filing emphasizes the reduction in "potential dilution and associated market overhang," indicating this was a material equity issuance arrangement.
View raw filing on EDGAR →The filing discloses results of the Company's 2026 Annual Meeting of Shareholders held on June 11, 2026, with voting outcomes on four proposals: election of four directors, ratification of the independent auditor (CBIZ CPAs P.C.), advisory approval of named executive officer compensation, and approval of an amendment to the Equity Incentive Plan increasing authorized shares by 1,750,000. Item 5.07 explicitly presents detailed voting tallies for each proposal, which is the core disclosure required for shareholder vote results under the 8-K taxonomy.
View raw filing on EDGAR →The 8-K discloses results of Biofrontera's Annual Meeting of Stockholders held on June 11, 2026, under Item 5.07. The filing reports three matters voted on: election of two Class II directors (Beth J. Hoffman, Ph.D. and Kevin D. Weber), approval of an amendment to the 2021 Omnibus Incentive Plan increasing authorized shares from 3.75M to 8.75M, and ratification of CBIZ CPAs P.C. as independent auditor. These are routine but material shareholder votes affecting governance and equity authorization.
View raw filing on EDGAR →Karen Hawkins, Chief Financial Officer and Secretary of Optex Systems Holdings, Inc., notified the Company on June 12, 2026 of her intention to resign effective December 31, 2026. The departure of a CFO is a material executive change that would affect a reasonable investor's assessment of the registrant's financial leadership and continuity. The filing explicitly states no disagreements or accounting issues were involved, confirming this is a straightforward departure disclosure.
View raw filing on EDGAR →The filing discloses a letter agreement with Stavros Vizirgianakis, the Chairman, in connection with his appointment as Executive Chairman. The material substance is the Board's approval of a 450,000 RSU grant under the 2023 Share Incentive Plan with a three-tranche vesting schedule. While the appointment itself is mentioned, the filing centers on the compensatory arrangement—the equity grant—which is the principal disclosed action and would materially affect investor assessment of executive compensation and dilution.
View raw filing on EDGAR →The filing discloses Item 5.07 results from Hepion Pharmaceuticals' 2026 Annual Meeting of Stockholders held on June 17, 2026, including voting outcomes on three proposals: election of five directors (Gary Stetz, Vincent LoPriore, Michael Purcell, Sireesh Appajosyula, and Chase LoPriore), ratification of Grassi & Co. as independent auditors, and approval of an amendment to the 2023 Omnibus Equity Incentive Plan to increase authorized shares to 8,000,000. These shareholder votes are material to investors as they determine board composition and equity plan capacity.
View raw filing on EDGAR →The filing discloses Item 3.01 notification from Nasdaq that Vestand Inc. failed to regain compliance with the Minimum Bid Price Requirement (Rule 5550(a)(2)) during its 180-calendar-day compliance period ending June 10, 2026, and is ineligible for an additional compliance period. The company faces a Nasdaq Hearings Panel determination on continued listing, with suspension and delisting risk pending the outcome of its appeal. This is a material delisting risk event.
View raw filing on EDGAR →Eva Live Inc. announced the formation of its first wholly owned subsidiary, Eva Defense Inc., described as a "strategic initiative designed to pursue acquisitions and partnerships within the rapidly growing drone, autonomous systems, and defense technology sectors." While this is a corporate restructuring event involving the creation of a subsidiary for M&A purposes, it does not constitute a completed acquisition, disposition, merger, or change of control (which would trigger ma_activity). The disclosure is material as it signals a strategic pivot and capital allocation toward a new business segment, but the event itself—subsidiary formation—does not fit cleanly into the more specific event categories.
View raw filing on EDGAR →The filing references a "Common Shares Purchase Agreement dated June 16, 2026" as Exhibit 10.1, which is the hallmark disclosure of a dilutive equity issuance. Although the Item 3.02 section itself is not provided in full, the exhibit and the boilerplate language disclaiming any offer to sell shares are consistent with a private placement or PIPE transaction. The presence of an executed purchase agreement for common shares indicates a material equity issuance that would dilute existing shareholders.
View raw filing on EDGAR →The filing discloses a firm commitment underwritten offering of 592,270 shares of common stock and 296,135 warrants, with gross proceeds of approximately $5.95 million (inclusive of over-allotment exercise). This is a registered equity issuance under an effective S-3 shelf registration statement, representing a dilutive capital raise material to investors' assessment of ownership and capital structure.
View raw filing on EDGAR →This press release announces a landmark partnership between Braiin and BillCentral Pty Ltd to deploy Braiin's Agentic AI customer experience platform across enterprise operations in Australia. The disclosure emphasizes this as a "major milestone" and "significant validation point" for Braiin's CXaaS strategy, expected to accelerate commercial rollout and validate platform capabilities in a live enterprise environment. While the filing does not specify contract value or quantify revenue impact, the CEO's statement that this "materially strengthen[s] our strategic position" and creates "highly scalable and recurring SaaS revenue model" opportunities, combined with the company's positioning in a $20B+ market, indicates material operational and strategic significance to a reasonable investor assessing the company's growth trajectory and market validation.
View raw filing on EDGAR →The filing discloses cancellation of 7.1 million pre-funded warrants pending a legal investigation into suspected misconduct including collusion, beneficial ownership cap violations, use of foreign nominees, and transfer agent discrepancies. While this involves warrant cancellation and regulatory/legal concerns, it does not fit neatly into the specific categories (not a litigation disclosure per se, not a covenant breach, not a delisting notice). The material nature of the investigation and warrant cancellation warrants classification as a material event outside the standard taxonomy.
View raw filing on EDGAR →Hozefa Lokhandwala was appointed as Executive Vice President and Chief Financial Officer effective June 16, 2026, with a base salary of $750,000, target bonus of 100%, annual equity grants of $750,000, and severance provisions.
View raw filing on EDGAR →AMC Global Media held its annual meeting of stockholders on June 16, 2026, with voting results disclosed on four proposals: election of Class A and Class B directors, ratification of KPMG LLP as independent auditor, advisory approval of named executive officer compensation, and approval of the Amended and Restated 2011 Stock Plan for Non-Employee Directors.
View raw filing on EDGAR →Cosan discloses that Radar Group (a subsidiary holding agricultural properties with Cosan investments) has entered into a "purchase and sale commitment agreement" for disposal of 41,214 hectares (12% of Radar's portfolio) in Mato Grosso for BRL 1.85 billion total consideration, with approximately BRL 586 million attributable to Cosan's interest. This is a material disposition of assets aligned with the company's stated strategy of "divestments, deleveraging, and portfolio simplification," meeting the definition of ma_activity under Item 1.02 or 2.01 of the 8-K taxonomy.
View raw filing on EDGAR →Dell disclosed the issuance of 3,438,364 shares of Class C common stock upon conversion of Class B common stock held by Silver Lake entities. While technically a conversion rather than a new issuance, this represents a dilutive equity event involving unregistered securities (relying on Section 3(a)(9) exemption) and a material change in the capital structure, with Class B shares declining from approximately 47.8M to 44.4M outstanding. The conversion by a significant shareholder (Silver Lake) is material to investors assessing ownership and control dynamics.
View raw filing on EDGAR →The disclosure announces preliminary clinical observations supporting evaluation of ELI-002 7P in combination with checkpoint inhibition and plans for a Phase 1 study in metastatic KRAS pancreatic cancer. This is a material clinical development milestone for a biopharmaceutical company, but does not fit neatly into more specific event categories (not an earnings release, not a formal restatement, not an impairment). The clinical progress and future study plans would affect investor assessment of the company's pipeline and prospects.
View raw filing on EDGAR →The filing discloses a material litigation development: a Supreme Court ruling on June 13, 2026 that granted in part and denied in part Fleming Intermediate Holdings LLC's motion to dismiss James River's amended complaint seeking damages for breach of contract related to a failed transaction closure. The Court allowed the Company's claims for direct damages to proceed, which represents a significant litigation milestone affecting the registrant's potential recovery and financial exposure.
View raw filing on EDGAR →The filing discloses Jabil Inc.'s results of operations for the third fiscal quarter ended May 31, 2026, via a press release furnished as Exhibit 99.1. This is a standard quarterly earnings release under Item 2.02, which is material to investors as it provides financial performance data essential to assessing the registrant's operational results and financial condition.
View raw filing on EDGAR →Fathom Holdings Inc. entered into a Merger Agreement with Bed Bath & Beyond Inc. on June 16, 2026, whereby Fathom will merge with a wholly-owned subsidiary of Bed Bath & Beyond, with Fathom surviving as a subsidiary of Bed Bath & Beyond. The merger consideration is 0.2236 shares of Parent common stock per Fathom share plus cash in lieu of fractional shares.
View raw filing on EDGAR →Marco Fregenal was terminated as Chief Executive Officer, Principal Financial Officer, and Principal Accounting Officer, effective immediately, following an internal review that found conduct inconsistent with the Company's Code of Ethics. He also resigned as a director.
View raw filing on EDGAR →Playboy held its 2026 Annual Meeting of Stockholders on June 16, 2026, with shareholders voting on five proposals: election of two Class III directors (Tracey Edmonds and James Yaffe), approval of an amendment to the 2021 Equity and Incentive Compensation Plan increasing available shares by 10 million, ratification of RSM US LLP as independent auditors, a non-binding Say on Pay vote, and approval of an adjournment proposal. All proposals passed with detailed vote tallies disclosed.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from Energy Focus's annual meeting held June 12, 2026, reporting the election of seven directors and ratification of GBQ Partners LLC as independent auditor. Item 5.07 explicitly requires disclosure of voting results at stockholder meetings, and the filing presents certified vote tallies for both proposals with detailed breakdowns of votes for, against, and withheld/abstained.
View raw filing on EDGAR →This Item 5.07 disclosure reports the results of Forward Air Corporation's annual stockholder meeting held on June 17, 2026, including voting outcomes on four proposals: election of five directors, advisory vote on named executive officer compensation, ratification of KPMG LLP as independent auditor, and approval of an amendment to the 2025 Omnibus Incentive Compensation Plan. The filing presents vote tallies (For, Against, Abstentions, Broker Non-Votes) for each proposal, which is the standard format for shareholder vote results disclosures.
View raw filing on EDGAR →The Board elected Roelof Botha as an independent director effective immediately to fill an existing vacancy, and appointed him to the Audit Committee. The disclosure centers on the appointment of a new director with significant public company and audit committee experience, making this a clear exec_appointment event. The related family employment disclosure and indemnification agreement are ancillary to the principal action of taking a board role.
View raw filing on EDGAR →